Cerenis Therapeutics SA announced that it has in-licensed Intellectual Property (IP) supporting an investigational new treatment of aortic valve stenosis (AVS) based on HDL therapy.
According to a press release by Cerenis, this technology is based on the findings of a study led by Jean-Claude Tardif, M.D. at the Montreal Heart Institute Research Centre in Canada.
AVS is characterized by a narrowing of the aortic valve, which can obstruct the flow of oxygenated blood from the heart to the rest of the body.
As the heart works harder to compensate for the obstruction, the heart muscle thickens and can cause a potentially dangerous imbalance in blood pressure between the heart and body.
Symptoms of severe AVS can include angina and syncope (fainting), and major complications can include heart failure and sudden death.
AVS is the most common form of heart valve disease in Western countries, resulting in more than 50,000 aortic valve replacement surgeries each year in the US.
Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases.
SOURCE:AGIPNEWS
